Valeant Pharmaceuticals (VRX) PT Lowered to $19 at Deutsche Bank

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. AVAV
4. BAC
5. UNH
6. ORCL
7. DVLT
8. LQDA
9. ACI
10. META

Go back to Valeant Pharmaceuticals (VRX) PT Lowered to $19 at Deutsche Bank

Valeant Pharma (VRX) Falls Another 4%

March 7, 2017 9:43 AM EST

Valeant Pharma (NYSE: VRX) is down another 4.1% early to $11.90, a fresh multi-year low. Deutsche Bank cut its price target to $19 earlier and Wells Fargo David Maris reiterated that new debt will lower EPS.

... More

Valeant (VRX) Refinancing will Lower Consensus EPS and Likely Means $8B in Asset Sales 'Off the Table' - Wells Fargo's Maris

March 6, 2017 10:32 AM EST

Wells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company announced it intends to refinance some of its debt.

Maris said while they are "still working through how much this will negatively impact consensus EPS, but... More

Mizuho Securities Reiterates Underperform Rating and $9 PT on Valeant Pharmaceuticals (VRX); 'Debt Refinance May Decrease Earnings' 'Cloudy Outlook'

March 6, 2017 9:18 AM EST

Mizuho Securities analyst Irina Koffler reiterates Underperform rating and $9 price target on Valeant Pharmaceuticals (NYSE: VRX), as the company announced a debt refinancing, that may increase interest expenses and decrease earnings to shareholders.

Koffler comments, "The company is using its recently... More